dexmedetomidine + bupivacaine (Assiut University)

Dexmedetomidine + bupivacaine is a combination of a highly selective alpha-2 adrenergic agonist and a long-acting amide-type local anesthetic. In clinical investigations conducted by **Assiut University**, this combination is being evaluated for its efficacy in ultrasound-guided transversus abdominis plane (TAP) blocks to manage postoperative pain in patients undergoing lower abdominal cancer surgeries. Dexmedetomidine acts as an adjuvant to bupivacaine, aiming to prolong the duration of the sensory blockade and enhance the quality of analgesia. The mechanism of action involves bupivacaine's inhibition of voltage-gated sodium channels, which prevents the generation and conduction of nerve impulses, and dexmedetomidine's activation of peripheral alpha-2 adrenergic receptors, which may reduce the release of norepinephrine and provide direct analgesic effects. This combination is intended to provide superior preemptive analgesia and reduce the requirement for systemic opioids in the postoperative period.

Other names

USG-STAP + bupivacaine + dexmedetomidinesubcostal transversus abdominis plane block with bupivacaine and dexmedetomidine